Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
Protara Therapeutics, Inc. (Nasdaq: TARA) announced participation in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on February 9, 2023, at 11:20 am ET in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protara Therapeutics, Inc. (Nasdaq: TARA) announced participation in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on February 9, 2023, at 11:20 am ET in New York. The event aims to discuss the company’s efforts in developing transformative therapies for cancer and rare diseases. Protara’s lead program, TARA-002, is an investigational therapy for non-muscle invasive bladder cancer and lymphatic malformations. The webcast will be available on the Company’s website and archived for a limited period.
Details
News Market Reaction – TARA
The recorded move for TARA in the trading session of this news was +4.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023 at 11:20 am ET in New York, New York.
The live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.